Prothena appoints Daniel G. Welch as Director and Chair Designate
Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced yesterday the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate following a comprehensive search process in connection with the board’s regular succession planning. Upon election […]
Matica Bio designates Paul Kim as CEO
Matica Biotechnology, Inc., a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), yesterday announced the appointment of Paul Kim as chief executive officer (CEO). As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities in the U.S. and […]
Molecular Partners and Orano Med collaborate to develop novel Radio-DARPin therapeutics
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in targeted alpha therapy, have announced a collaboration to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their […]
Bristol Myers Squibb acquires Karuna Therapeutics
Bristol Myers Squibb and Karuna Therapeutics, Inc. recently announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved […]
Henry Schein onboards Carole T. Faig as new independent Director
Henry Schein, Inc., a provider of health care solutions to office-based dental and medical practitioners, announced yesterday that its Board of Directors has appointed Carole T. Faig as an independent director to serve until the 2024 Annual Meeting of Stockholders in May, when she is expected to stand for re-election to the Board by a […]
GEDi Cube and Renovaro Biosciences enter into an agreement
GEDi Cube Intl Ltd., an AI medical technology company, and Renovaro Biosciences Inc. (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in […]
HebeCell and Logomix collaborate to develop gene-edited NK cells
HebeCell Corp (HebeCell), a biotechnology company developing ProtoNK™ cell therapeutics based on its proprietary 3D PSC-NK manufacture platform, and Logomix Inc (Logomix), a Tokyo-based synthetic biology company, with a platform technology to engineer-in complex genomic messages of ~Mb-scale into human cells, recently announced a strategic partnership to research and develop gene-edited NK cells and discover genetic […]
Ligandal Inc. Appoints Tushar Nuwal for two leadership roles
Ligandal Inc., an early-stage genetic medicine biotechnology company, announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Business Officer. Mr. Nuwal brings 20 years of biopharmaceutical experience, including roles at small and large pharmaceutical companies. “We are elated to welcome Tushar to Ligandal. His experience in negotiating multi-billion-dollar pharmaceutical transactions and his […]
Biocytogen Pharmaceuticals signs a License Agreement With Pheon Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotech company focusing on the discovery of novel antibody therapeutics, yesterday announced an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. Under the terms of the agreement, Pheon will develop and commercialize an […]
CRO company TriApex completes Series C financing round led by Legend Capital
TriApex Laboratories Co., Ltd recently announced the completion of its Series C financing round, which was led by Legend Capital. This funding milestone will help TriApex continue to lead in the field of special diseases and devote itself to providing non-clinical data with more clinical value, accelerating the international expansion of integrated R&D services from […]